Home/Investors/Vertex Ventures HC

Vertex Ventures HC

Biotech Investor · 8 portfolio companies

Portfolio

8

Combined Value

$524.2M

Focus Areas

10

Top Stage

phase-1

Investment Focus

Neuroscience Immunology Inflammation Genetics & Genomics Rare Disease Oncology Autoimmune Diseases Inflammatory Diseases Ophthalmology Regenerative Medicine

Portfolio Companies

Company	Stage	Valuation	Focus
Contineum Therapeutics	Phase 2	$524.2M	Neuroscience, Immunology
Ascidian Therapeutics	preclinical	—	Genetics & Genomics, Rare Disease
Matchpoint Therapeutics	preclinical	—	Immunology
Indapta Therapeutics	Phase 1	—	Oncology, Autoimmune Diseases
Sonoma Biotherapeutics	Phase 1	—	Autoimmune Diseases, Inflammatory Diseases
Scorpion Therapeutics	phase-1	—	Oncology
Obsidian Therapeutics	phase-1	—	Oncology
Sironax	phase-1	—	Ophthalmology, Neuroscience

Frequent Co-Investors

Atlas Venture2 shared ARCH Venture Partners2 shared Public market investors1 shared Frazier Life Sciences1 shared GV1 shared Boxer Capital1 shared Mubadala Capital1 shared Alexandria Venture Investments1 shared